Saturday, February 14, 2026 2/14/2026

Esterase-sensitive hyperpolarized 13C probes for simultaneous imag

Award Number: R01EB027698
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/05/2020
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Esterase-sensitive hyperpolarized 13C probes for simultaneous imag - PROJECT SUMMARY: Abnormal metabolism is associated with a number of metabolic diseases such as cancer, diabetes, and cardiovascular diseases. Important markers for the altered metabolic states include changes in fuel preferences and loss of acidity regulations in tissues. To date, routine assessments of energy metabolism and acidity in viable tissues remain a challenge. Sensitive imaging modalities that can provide accurate characterization of these important biomarkers are therefore highly desirable. In this application, we aim to establish a series of hyperpolarized (HP) 13C-enriched molecules that can be activated by an endogenous enzyme esterase to produce both pH and metabolic imaging probes in tissues. Successful development of these HP 13C-enriched compounds will allow for tissue acidity and metabolic information to be simultaneously characterized following an injection of a single imaging probe. Molecular candidates for these applications must be chemically stable, can be highly polarized by dynamic nuclear polarization (DNP), have long 13C T1’s, and be highly sensitive to esterase hydrolysis. Once hydrolyzed, the molecules must quickly decompose to form a pair of pH imaging probes, HP 13CO2 and HP H13CO3-, as well as a HP 13C-enriched metabolic substrate such as 13C- pyruvate. Here, we propose a series of ethyl alkyl mixed anhydride carbonate compounds with 13C- enrichments at both the carbonate and carboxyl carbons. These carbon centers have long T1 making them suitable for HP 13C imaging applications. Moreover, these small organic molecules are expected to be efficiently polarized by DNP with significantly improved 13C MR imaging sensitivity. Last but not least, the ester functional group in these mixed anhydrides is expected to be highly susceptible to hydrolysis by esterase. Once injected into the circulation, we expect that these HP 13C-mixed anhydride carbonates will be rapidly hydrolyzed by esterase producing monoacyl carbonate molecules. These intermediates are expected to decompose, producing HP 13CO2 and a HP 13C-enriched metabolic substrate for pH measurement and metabolism analysis in tissues, respectively. In Aim 1 of this study, we will synthesize 13C-enriched ethyl acyl mixed anhydride carbonates with 13C-acetate, 13C-pyruvate, or 13C-butyrate as the acyl moiety. HP 13C parameters such as T1, signal enhancement and chemical stability of these compounds will also be evaluated. In Aim 2, we will investigate the production of HP 13CO2/H13CO3- and HP 13C metabolic substrate by esterase hydrolysis in solutions of isolated esterase, isolated rat plasma, blood, and homogenates of rat liver and heart tissues. Finally, we will evaluate the acute toxicity as well as the in vivo imaging efficacy of these HP 13C probes in mice and rats (Aim 3). Successful execution of this study could lead to a series of HP 13C imaging probes that allow for simultaneous imaging of tissue pH and energy metabolism in tissues associated with metabolic diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$6,135 )
2025	2023	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	5	11/25/2024	NON-COMPETING CONTINUATION	-$6,135
														Subtotal = -$6,135

Issue Date FY: 2023 ( Subtotal = $343,125 )
2023	2023	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	5	1/26/2023	NON-COMPETING CONTINUATION	$34,312
2023	2023	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	5	11/9/2022	NON-COMPETING CONTINUATION	$308,813
														Subtotal = $343,125

Issue Date FY: 2022 ( Subtotal = $343,125 )
2022	2022	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	4	6/27/2022	NON-COMPETING CONTINUATION	$34,313
2022	2022	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	11/16/2021	NON-COMPETING CONTINUATION	$308,812
														Subtotal = $343,125

Issue Date FY: 2021 ( Subtotal = $336,262 )
2021	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	3	3/27/2021	NON-COMPETING CONTINUATION	$27,450
2021	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	10/27/2020	NON-COMPETING CONTINUATION	$308,812
2021	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	3	4/30/2021	NON-COMPETING CONTINUATION	$0
2021	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	005	3	5/29/2021	NON-COMPETING CONTINUATION	$0
2021	2020	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	003	1	5/8/2021	NEW	-$8,151
2021	2020	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	004	2	5/8/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$8,151
														Subtotal = $336,262

Issue Date FY: 2020 ( Subtotal = $326,771 )
2020	2020	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	1	8/21/2020	NEW	-$304,552
2020	2020	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	2	8/22/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$275,481
2020	2020	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	1/28/2020	NEW	$355,842
														Subtotal = $326,771

Grand Total All Awards = $1,343,148

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Esterase-sensitive hyperpolarized 13C probes for simultaneous imag

Award Number: R01EB027698

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/05/2020

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer